---
title: "Prime Medicine says New Zealand clears clinical trial application for Wilson disease therapy PM577a"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290194432.md"
description: "Prime Medicine received New Zealand Medsafe clearance for a clinical trial application of PM577a, a therapy for H1069Q-mutated Wilson disease. This authorization permits a global, open-label Phase 1/2 first-in-human study, with the trial expected to commence in the second half of 2026. Initial clinical data from the study are anticipated to be available in 2027."
datetime: "2026-06-18T12:03:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290194432.md)
  - [en](https://longbridge.com/en/news/290194432.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290194432.md)
generator: "portal-rs"
---

# Prime Medicine says New Zealand clears clinical trial application for Wilson disease therapy PM577a

-   Prime Medicine secured New Zealand Medsafe clearance for a clinical trial application for PM577a in H1069Q-mutated Wilson disease. \* The authorization enables a global, open-label Phase 1⁄2 first-in-human study; trial start is expected in 2H 2026. \* Initial clinical data are expected in 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prime Medicine Inc. published the original content used to generate this news brief on June 18, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [PRME.US](https://longbridge.com/en/quote/PRME.US.md)

## Related News & Research

- [07:45 ETMagaya Expands New Zealand Capabilities with PortConnect Integration](https://longbridge.com/en/news/297511398.md)
- [Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML | APVO Stock News](https://longbridge.com/en/news/297911849.md)
- [TScan Therapeutics cuts workforce 75% in reorganization to focus on in vivo solid tumor cell therapy](https://longbridge.com/en/news/297773935.md)
- [Koala trial doses first patient with novel KMA‑targeting CAR‑T](https://longbridge.com/en/news/298021066.md)
- [HaemaLogiX doses first patient with KMCAR T-cell in KOALA trial](https://longbridge.com/en/news/298029912.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**